Business
Press Release Dec 26 2022
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 26, 2022, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe".
About this update from Alembic Pharmaceuticals Limited
[{"type":"text","content":" Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 26, 2022, titled \"Alembic Pharmaceuticals receives USFDA Final Approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe\". View Attachment","length":429,"tagName":"div"}]